Promoting Clinical Trials APAC, 29-30 January 2013, Singapore

Main Category: Conferences
Article Date: 09 Jan 2013 - 4:00 PST


Following on from their successful conference in Dubai: Promoting Clinical Trials MENA, Qatalyst Global host the second Promoting Clinical Trials conference in Singapore on the 29th and 30th January 2013.This event will bring together key influencers from the Asian Pacific (APAC) healthcare, clinical research, and pharmaceutical industries to discuss the current clinical trials environment in the region.

The increasing costs of medicine and healthcare in Western countries, caused by factors such as time consumption in clinical trials and the increasing costs of developing new drugs, has influenced many large and multi-national pharmaceutical and clinical research organisations (CROs) to outsourcing to the APAC region. The growth of outsourcing here can be seen in the significant rise in early phase trials conducted in Asia; where the number of registered trials reached almost 20,000 in March last year and the increase in multinational pharmaceutical and biopharmaceutical companies planning further expansion into the APAC through First-in-Human trials within the next two years.

The APAC region is providing these organisations with a large varied demographic area to test upon, making patient selection time faster and easier, and also local government support for growth and improvement in infrastructure and investment in the future of medicine. This investment in research and development of new drugs is one of the major factors influencing multinational pharmaceutical companies to expand into the APAC region. The management company PRTM (now PWC) found in a study in 2009-2010 that although multinational CROs are continuously growing in influence and expanding in size, they are also working hard to merge the local CRO operational processes with those of their global CROs in the respective regions. At that point in time, more than 90% of the Asian trials were of a multinational scale.

Chair of the conference is Dr. Amar Kureishi, Head of Drug Development Asia at Quintiles, will be moderating the event, with confirmed representatives including: Dr. Ajay Gautam, Executive Director of Research & Development Strategy & Head Emerging Markets, AstraZeneca, Dr. Jerry Chng and Rebecca Dai, Medical Director and Global Clinical Management Lead respectively, Bayer, Maggie Lim, Director of Asia Pacific Clinical Development, GlaxoSmithKline, Dr. Timothy Low, Vice President of Medical Affairs, Covidien, as well as key influencers from local and cross-national CROs, healthcare and educational peers. They will be covering topics including:

• Discussing promotional initiatives for encouraging international Research and Development
• Analysis of the priorities for selecting which CRO to partner with
• Evaluating the challenges and advantages for outsourcing and expanding, including cultural differences, qualified data and the current limited number of trained CRA's
• Discovering the best practice for site selection and patient recruitment

You can register for the conference by contacting Qatalyst Global directly on +44 (0)203 207 9322 or info@qatalystglobal.com. Pharmaceutical, hospital and regulatory member's passes are $999 (USD) and Vendor passes are $2,295(USD).

For more information on the Promoting Clinical Trials APAC, visit our website http://www.promotingclinicaltrials.com or contact:
Kudsia Kaker
Event Director, Qatalyst Global
kudsia@qatalystglobal.com
(UK) +44 (0)203 207 9322 (US) +1 212 537 6203
27-28 St Clements House, Clements Lane, London, EC4N 7AE, UK
http://www.qatalystglobal.com

• Additional
• References
• Citations